CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+17.6%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.89B
AUM Growth
+$1.89B
(+9.7%)
Cap. Flow
-$15.2M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
59.01%
Holding
53
New
4
Increased
8
Reduced
11
Closed
6
Top Buys
| 1 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$33.9M |
| 2 |
Avidity Biosciences
RNA
|
$28.7M |
| 3 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$18.2M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$15.2M |
| 5 |
AnaptysBio
ANAB
|
$11.5M |
Top Sells
| 1 |
Arcellx
ACLX
|
$23M |
| 2 |
Biohaven
BHVN
|
$20M |
| 3 |
Sarepta Therapeutics
SRPT
|
$19.8M |
| 4 |
Cullinan Oncology
CGEM
|
$19.6M |
| 5 |
Insmed
INSM
|
$12.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $428M | 22.71% | 8,494,151 | – | – |
|
2
Vaxcyte
PCVX
$4B
| $114M | 6.06% | 1,000,000 -100,000 | -9% | -$11.4M |
|
|
3
Arcellx
ACLX
$3.85B
| $104M | 5.54% | 1,250,000 -275,000 | -18% | -$23M |
|
|
LBPH
4
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $93M | 4.93% | 2,790,462 | – | – |
|
5
Edgewise Therapeutics
EWTX
$1.51B
| $90.9M | 4.82% | 3,406,534 +400,000 | +13% | +$10.7M |
|
6
EyePoint Pharmaceuticals
EYPT
$797M
| $66.5M | 3.53% | 8,325,000 | – | – |
|
|
RAPP
7
Rapport Therapeutics
RAPP
$643M
| $60.2M | 3.19% | 2,940,921 +638 | +0% | +$13.1K |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $56.2M | 2.98% | 1,100,000 -250,000 | -19% | -$12.8M |
|
9
Praxis Precision Medicines
PRAX
$958M
| $50.1M | 2.65% | 870,000 +185,000 | +27% | +$10.6M |
|
10
Corbus Pharmaceuticals
CRBP
$115M
| $49M | 2.6% | 2,375,000 +350,000 | +17% | +$7.22M |
|
|
11
Avidity Biosciences
RNA
$5.99B
| $48.2M | 2.56% | 1,050,000 +625,000 | +147% | +$28.7M |
|
12
Janux Therapeutics
JANX
$1.37B
| $47.7M | 2.53% | 1,050,000 | – | – |
|
13
BridgeBio Pharma
BBIO
$9.89B
| $47.3M | 2.51% | 1,858,351 | – | – |
|
14
NewAmsterdam Pharma
NAMS
$2.71B
| $41M | 2.17% | 2,470,000 +170,000 | +7% | +$2.82M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $41M | 2.17% | 2,561,600 +950,000 | +59% | +$15.2M |
|
16
Merus
MRUS
$4.98B
| $37M | 1.96% | 740,000 -100,000 | -12% | -$5M |
|
17
CG Oncology
CGON
$2.04B
| $36.8M | 1.95% | 975,000 | – | – |
|
|
18
Insmed
INSM
$28.8B
| $36.5M | 1.94% | 500,000 -175,000 | -26% | -$12.8M |
|
19
Biomea Fusion
BMEA
$116M
| $36.1M | 1.91% | 3,570,872 | – | – |
|
20
Axsome Therapeutics
AXSM
$6.05B
| $35.9M | 1.91% | 400,000 | – | – |
|
|
BIOA
21
BioAge Labs, Inc. Common Stock
BIOA
$177M
| $33.9M | 1.8% | +1,629,529 | New | +$33.9M |
|
|
BBOT
22
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $30.4M | 1.61% | 2,909,000 | – | – |
|
23
Pharvaris
PHVS
$1.39B
| $27.2M | 1.44% | 1,466,460 | – | – |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $24.5M | 1.3% | 2,130,000 | – | – |
|
|
ALMS
25
Alumis Inc. Common Stock
ALMS
$479M
| $22.9M | 1.22% | 2,147,396 -4 | -0% | -$43 |
|